Tirzepatide vs Dulaglutide for Heart Protection: Did the SURPASS-CVOT Trial Reveal a Cardiovascular Ceiling?

This is an expert commentary/editorial analyzing the results of the SURPASS-CVOT trial. SURPASS-CVOT was a large cardiovascular outcomes trial that used an active comparator design (tirzepatide vs dulaglutide) rather than a placebo-controlled design, reflecting the ethical reality that placebo-controlled trials are no longer appropriate when effective treatments exist. The commentary also discusses an imputed placebo analysis to estimate the absolute cardiovascular benefit of tirzepatide.

This raises a fundamental question for metabolic medicine: if dramatically better weight loss and blood sugar control don't proportionally improve heart outcomes, have we reached the limit of what incretin-based drugs can do for cardiovascular protection? With billions being invested in triple and multi-agonist drugs, the answer has enormous implications for drug development strategy and patient care priorities.

The incretin drug race has been defined by achieving ever-greater weight loss and metabolic improvement. SURPASS-CVOT challenges the assumption that more weight loss automatically means more heart protection. If the cardiovascular benefit of GLP-1-based drugs has a ceiling, the industry's push toward triple agonists (like retatrutide) may need to be justified by benefits beyond heart protection — such as liver disease, kidney protection, or quality of life. This commentary suggests the field may need entirely new paradigms to further reduce cardiovascular risk in diabetes.

This is a commentary by a single author, not a primary research study. The SURPASS-CVOT trial used an active comparator rather than placebo, making it harder to demonstrate superiority since dulaglutide itself provides cardiovascular benefits. The imputed placebo analysis is a statistical estimation, not a direct comparison. The commentary notes that exploratory findings on mortality and kidney function should be interpreted cautiously.